A new trading day began on Tuesday, with BridgeBio Pharma Inc (NASDAQ: BBIO) stock price down -4.48% from the previous day of trading, before settling in for the closing price of $34.57. BBIO’s price has ranged from $21.62 to $39.47 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 574.82%. Meanwhile, its annual earnings per share averaged -27.61%. With a float of $155.43 million, this company’s outstanding shares have now reached $190.04 million.
Let’s determine the extent of company efficiency that accounts for 730 employees. In terms of profitability, gross margin is 97.67%, operating margin of -265.69%, and the pretax margin is -244.34%.
BridgeBio Pharma Inc (BBIO) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of BridgeBio Pharma Inc is 18.28%, while institutional ownership is 76.09%. The most recent insider transaction that took place on Mar 25 ’25, was worth 2,764,943. In this transaction Chief Executive Officer of this company sold 75,000 shares at a rate of $36.87, taking the stock ownership to the 4,948,447 shares. Before that another transaction happened on Mar 06 ’25, when Company’s Director sold 12,875 for $32.58, making the entire transaction worth $419,500. This insider now owns 1,764 shares in total.
BridgeBio Pharma Inc (BBIO) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.83 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -27.61% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 52.81% during the next five years compared to -3.04% drop over the previous five years of trading.
BridgeBio Pharma Inc (NASDAQ: BBIO) Trading Performance Indicators
Here are BridgeBio Pharma Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.67. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 28.30.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.85, a number that is poised to hit -0.91 in the next quarter and is forecasted to reach -2.62 in one year’s time.
Technical Analysis of BridgeBio Pharma Inc (BBIO)
Looking closely at BridgeBio Pharma Inc (NASDAQ: BBIO), its last 5-days average volume was 2.04 million, which is a drop from its year-to-date volume of 3.05 million. As of the previous 9 days, the stock’s Stochastic %D was 34.16%. Additionally, its Average True Range was 1.64.
During the past 100 days, BridgeBio Pharma Inc’s (BBIO) raw stochastic average was set at 63.66%, which indicates a significant increase from 23.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.04% in the past 14 days, which was lower than the 61.50% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $34.24, while its 200-day Moving Average is $28.38. However, in the short run, BridgeBio Pharma Inc’s stock first resistance to watch stands at $34.07. Second resistance stands at $35.11. The third major resistance level sits at $35.73. If the price goes on to break the first support level at $32.41, it is likely to go to the next support level at $31.79. Should the price break the second support level, the third support level stands at $30.75.
BridgeBio Pharma Inc (NASDAQ: BBIO) Key Stats
With a market capitalization of 6.28 billion, the company has a total of 190,189K Shares Outstanding. Currently, annual sales are 221,900 K while annual income is -535,760 K. The company’s previous quarter sales were 5,880 K while its latest quarter income was -265,050 K.
